Puberty blockers and gender-affirming hormones are rarely prescribed to U.S. transgender and gender diverse (TGD) adolescents, according to a new study from researchers at Harvard T.H. Chan School of Public Health, Harvard Pilgrim Health Care Institute, and FOLX Health.
TxGNN improves drug repurposing by predicting treatments for rare diseases with no approved therapies
A new model, TxGNN, revolutionizes zero-shot drug repurposing by predicting treatments for diseases with no known therapies, offering improved accuracy and trust via interpretable AI
September 27, 2024